Gotham Asset Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16M | Sell |
374,708
-108,270
| -22% | -$5.88M | 0.04% | 660 |
|
|
2026
Q1 | $30.3M | Buy |
482,978
+323,810
| +203% | +$25.9M | 0.09% | 289 |
|
|
2025
Q4 | $15.2M | Sell |
159,168
-41,944
| -21% | -$4.11M | 0.06% | 498 |
|
|
2025
Q3 | $19.6M | Buy |
201,112
+126,595
| +170% | +$13.1M | 0.09% | 318 |
|
|
2025
Q2 | $8M | Buy |
74,517
+39,545
| +113% | +$4M | 0.05% | 536 |
|
|
2025
Q1 | $3.53M | Buy |
34,972
+23,542
| +206% | +$2.37M | 0.03% | 624 |
|
|
2024
Q4 | $1.02M | Buy |
11,430
+3,475
| +44% | +$306K | 0.01% | 913 |
|
|
2024
Q3 | $667K | Buy |
7,955
+1,840
| +30% | +$145K | 0.01% | 1020 |
|
|
2024
Q2 | $471K | Sell |
6,115
-231
| -4% | -$16.9K | 0.01% | 1097 |
|
|
2024
Q1 | $435K | Buy |
6,346
+1,338
| +27% | +$86K | 0.01% | 1096 |
|
|
2023
Q4 | $290K | Buy |
5,008
+849
| +20% | +$45.3K | 0.01% | 1148 |
|
|
2023
Q3 | $220K | Sell |
4,159
-20,535
| -83% | -$1.08M | ﹤0.01% | 1207 |
|
|
2023
Q2 | $1.34M | Buy |
24,694
+20,650
| +511% | +$1.08M | 0.03% | 682 |
|
|
2023
Q1 | $202K | Buy |
+4,044
| New | +$191K | ﹤0.01% | 1245 |
|
|
2022
Q2 | – | Sell |
-8,693
| Closed | -$385K | – | 1129 |
|
|
2022
Q1 | $385K | Buy |
8,693
+2,108
| +32% | +$91.4K | 0.01% | 874 |
|
|
2021
Q4 | $280K | Sell |
6,585
-100,854
| -94% | -$4.24M | 0.01% | 970 |
|
|
2021
Q3 | $4.66M | Buy |
107,439
+95,930
| +834% | +$4.24M | 0.19% | 149 |
|
|
2021
Q2 | $492K | Sell |
11,509
-2,156
| -16% | -$90.7K | 0.02% | 686 |
|
|
2021
Q1 | $528K | Buy |
13,665
+6,116
| +81% | +$231K | 0.02% | 663 |
|
|
2020
Q4 | $271K | Sell |
7,549
-2,161
| -22% | -$77.9K | 0.01% | 858 |
|
|
2020
Q3 | $371K | Sell |
9,710
-12,215
| -56% | -$471K | 0.01% | 798 |
|
|
2020
Q2 | $770K | Sell |
21,925
-1,543
| -7% | -$55.6K | 0.02% | 625 |
|
|
2020
Q1 | $766K | Buy |
+23,468
| New | +$917K | 0.02% | 617 |
|
|
2019
Q2 | – | Sell |
-19,943
| Closed | -$765K | – | 1139 |
|
|
2019
Q1 | $765K | Buy |
19,943
+10,099
| +103% | +$386K | 0.01% | 726 |
|
|
2018
Q4 | $348K | Sell |
9,844
-71
| -0.7% | -$2.58K | 0.01% | 837 |
|
|
2018
Q3 | $382K | Sell |
9,915
-49,745
| -83% | -$1.74M | 0.01% | 789 |
|
|
2018
Q2 | $1.95M | Buy |
+59,660
| New | +$1.8M | 0.03% | 480 |
|
|
2018
Q1 | – | Sell |
-503,669
| Closed | -$12.5M | – | 950 |
|
|
2017
Q4 | $12.5M | Buy |
503,669
+475,026
| +1,658% | +$13.1M | 0.18% | 178 |
|
|
2017
Q3 | $836K | Buy |
28,643
+4,046
| +16% | +$112K | 0.01% | 630 |
|
|
2017
Q2 | $682K | Sell |
24,597
-1,639,485
| -99% | -$43.5M | 0.01% | 696 |
|
|
2017
Q1 | $41.4M | Buy |
1,664,082
+1,564,698
| +1,574% | +$38M | 0.53% | 22 |
|
|
2016
Q4 | $2.15M | Buy |
+99,384
| New | +$2.17M | 0.03% | 495 |
|
|
2013
Q4 | – | Sell |
-18,744
| Closed | -$220K | – | 968 |
|
|
2013
Q3 | $220K | Sell |
18,744
-42,150
| -69% | -$456K | 0.01% | 845 |
|
|
2013
Q2 | $564K | Buy |
+60,894
| New | +$517K | 0.02% | 649 |
|
Other funds holding BSX
Gotham Asset Management's BSX Position: Q2 2026 in Review
Gotham Asset Management reduced its Boston Scientific (BSX) stake by 22% in Q2 2026, selling an estimated $5.88M and leaving 374,708 shares worth $16M. The position accounts for 0.04% of the portfolio, ranked #660.
Gotham Asset Management first reported a position in BSX in Q2 2013 and has held it in 34 quarters since. The position peaked at $41.4M in Q1 2017. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Gotham Asset Management held 374,708 shares of Boston Scientific worth $16M as of Q2 2026.
- Gotham Asset Management sold 108,270 Boston Scientific shares in Q2 2026, an estimated $5.88M.
- Boston Scientific made up 0.04% of Gotham Asset Management's portfolio in Q2 2026, its #660 holding.
- Gotham Asset Management first reported a position in Boston Scientific in Q2 2013 and has held it in 34 quarters since.
- Gotham Asset Management's Boston Scientific position peaked at $41.4M in Q1 2017.
- 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.